BGLC · BioNexus Gene Lab Corp
$1.49
-0.06 (-3.87%)
At close · Aug 31
Going-concern doubt
— cleared May 15, 2026
The latest filing states the doubt was alleviated.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon improving its operating results and maintaining adequate liquidity. Management believes that the Company’s existing cash balance, together with its positive working capital position, will provide sufficient liquidity to fund operations and meet its obligations as they become due for at least the next twelve months from the date these condensed consolidated financial statements are issued.”View the 10-Q filed May 15, 2026
Market Cap
$4.37M
Shares
2.93M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.49
Open$1.48
Day$1.48–1.49
52W close$1.32–6.00
Avg vol 30d15K
Short int7K · 0.2% float · 1.0d
Short vol36%
DataApr 2025–Aug 2026
Filing10-Q · Aug 14
Raw chart and full-history price indicators begin at the captured split on Apr 7, 2025; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.70
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−43%
below
Price vs 50-day avg
−12%
below
RSI (14)
44
neutral
MACD trend
Positive
52-week position
4%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+13%
trailing
6-month return
−40%
trailing
YTD return
−62%
this year
Relative strength
−54%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
+50% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.25% of float · ▲ +13.9% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
3 holders — mid 3-yr range
Squeeze score
35
low risk · 0–100
Fundamentals
Revenue growth
−22%
Y/Y
Gross margin
15%
expanding
EPS growth
+46%
Y/Y
Free cash flow
$-1.9M
Quant / Vol
risk profile
Volatility
74%
annualized · 1-yr
Max drawdown
−78%
past year
ATR
8.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−43%
Bearish
Price vs 50-day avg
−12%
Bearish
RSI (14)
44
Neutral
MACD trend
Positive
Bullish
52-week position
4%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
+50% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.25% of float · ▲ +13.9% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
3 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 4%
Range high $6
vs 200-day avg -43%
vs 50-day avg -12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Specialty Chemicals — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BGLC
this stock
BioNexus Gene Lab Corp
|
$4.37M | -62.3% | -21.9% | — | 0.2% |
|
LIN
Linde PLC
|
$225.65B | +14.8% | +3.0% | 31.6 | 1.1% |
|
AIQUF
L Air Liquide SA /Fi
|
$126.02B | +5.1% | — | — | 0.0% |
|
SHW
Sherwin Williams Co
|
$83.72B | +4.6% | +2.1% | 31.8 | 2.6% |
|
ECL
Ecolab Inc.
|
$80.38B | +7.9% | +2.2% | 38.5 | 1.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
Raw-price comparisons begin at the captured split on Apr 7, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BGLC | -6.3% | +12.9% | -40.4% | +12.9% | -62.3% |
| SPY | +0.5% | +1.2% | +13.3% | +2.7% | +12.5% |
| vs SPY | -6.8% | +11.6% | -53.7% | +10.2% | -74.8% |